
    
      Phase IIa trial of escalating doses of intravenous (i.v.) MSCs in active SLE, followed by a
      Phase IIb, triple blind, controlled assessment of the selected MSC dosing versus Placebo, in
      SLE patients receiving Standard of Care Therapy for Severe Renal Disease,
    
  